Lv11
8 积分 2025-06-02 加入
Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer
2分钟前
已完结
Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial
5分钟前
已完结
Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC
13天前
已完结
Association of Circulating Eosinophils With Systemic Immune Activation and Reduced Recurrence in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer
23天前
已完结
Efficacy and safety of trastuzumab with or without a tyrosine kinase inhibitor for HER2-positive breast cancer: A systematic review and meta-analysis
27天前
已完结
Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum
29天前
已完结
Exploring the immunological effects of antibody–drug conjugates
29天前
已完结
Real-world efficacy and safety of neoadjuvant immunochemotherapy in patients with triple-negative breast cancer
1个月前
已完结
Macrophages: Targets for next-generation cancer immunotherapy
1个月前
已完结
Advances in Systemic Treatment of Breast Cancer
1个月前
已完结
皖公网安备34019202002308
